The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc 11-Oct-2022 / 14:01 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interes...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc 10-Oct-2022 / 14:21 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interes...
The independent financial analyst theScreener just downgraded the general evaluation of NEKTAR THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date March...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see†phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see br...
Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .
We have taken a fresh look at Nektar following new data and the recent addition of trials in new indications for lead drug candidate bempegaldesleukin (or bempeg). After some adjustments to our model, we are maintaining our fair value estimate of $39 per share for the emerging biotech, and we are maintaining our no-moat rating. Our valuation is extremely sensitive to our assumptions of probability-weighted sales for bempeg, the firm's leading immuno-oncology candidate, which we model to reach ab...
We have taken a fresh look at Nektar following new data and the recent addition of trials in new indications for lead drug candidate bempegaldesleukin (or bempeg). After some adjustments to our model, we are maintaining our fair value estimate of $39 per share for the emerging biotech, and we are maintaining our no-moat rating. Our valuation is extremely sensitive to our assumptions of probability-weighted sales for bempeg, the firm's leading immuno-oncology candidate, which we model to reach ab...
We have taken a fresh look at Nektar following new data and the recent addition of trials in new indications for lead drug candidate bempegaldesleukin (or bempeg). After some adjustments to our model, we are maintaining our fair value estimate of $39 per share for the emerging biotech, and we are maintaining our no-moat rating. Our valuation is extremely sensitive to our assumptions of probability-weighted sales for bempeg, the firm's leading immuno-oncology candidate, which we model to reach ab...
We don't anticipate any changes to our fair value estimate of $39 per share for no-moat Nektar following its first-quarter results. The company's valuation is heavily based on the potential of its immuno-oncology pipeline. In the first quarter, the company earned $4.4 million in product sales, $11.4 million in royalties, $8.2 million in non-cash royalties, and $4.2 million in license and collaboration revenue. In sum, the $28 million in revenue represents a 26% decline from last year, with the d...
We don't anticipate any changes to our fair value estimate of $39 per share for no-moat Nektar following its first-quarter results. The company's valuation is heavily based on the potential of its immuno-oncology pipeline. In the first quarter, the company earned $4.4 million in product sales, $11.4 million in royalties, $8.2 million in non-cash royalties, and $4.2 million in license and collaboration revenue. In sum, the $28 million in revenue represents a 26% decline from last year, with the d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.